Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 May 24, 2016 Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial May 17, 2016 Announcements in conjunction with Theratechnologies annual meeting May 16, 2016 Update on Tesamorelin Marketing Authorization Application in Brazil Apr 28, 2016 Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial Mar 31, 2016 Theratechnologies Announces Financial Results for First Quarter of 2016 Mar 18, 2016 Theratechnologies and TaiMed Biologics sign exclusive Marketing and Distribution Agreement for Ibalizumab Mar 08, 2016 Mexico approves the 1mg/vial presentation of EGRIFTA® (tesamorelin for injection) Feb 24, 2016 Theratechnologies hires new Chief Financial Officer Feb 24, 2016 Theratechnologies Announces Financial Results for Fiscal Year 2015 Oct 01, 2015 Theratechnologies Announces Financial Results for Third Quarter of 2015 First page « Previous page ‹ … Page 28 Page 29 Page 30 Page 31 Current page 32 Page 33 Page 34 Page 35 Page 36 … Next page › Last page » Displaying 311 - 320 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
May 24, 2016 Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial
Mar 18, 2016 Theratechnologies and TaiMed Biologics sign exclusive Marketing and Distribution Agreement for Ibalizumab
